The purpose of this study is to assess the efficacy of LMWH treatment in women with unexplained infertility and negative immunological markers undergoing ICSI.
Inclusion criteria: 1. patients undergoing 1st trial ICSI 2. unexplained infertility 3. negative immunological markers including ACL abs, LAC, ANA, ATA, AnitdsDNA Exclusion criteria: 1. previous IVF/ICSI 2. Any cause of infertility 3. Suspected and/or unexpected poor response during ovulation induction 4. positive immunological markers 5. Age \> 40 years. All participants will undergo IVF/ICSI cycle using the Long luteal phase protocol. the dose of gonadotropins will be calculated according to patient age and BMI. All patients will have 2-3 embryos transferred at D5 according to their age. the primary outcome will be LBR. secondary outcomes will include biochemical pregnancy rate and clinical pregnancy rate.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
716
LMWH will be given on daily basis subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
0.9% saline solution will be given subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
Live birth Rate
Time frame: at delivery
Clinical Pregnancy Rate
Time frame: at 7 weeks of gestation
Biochemical Pregnancy Rate
Time frame: 14 days after embryo transfer
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.